Search
Parabilis Medicines Ord Shs
PBLSAdd to Watchlist
28.430USD
+0.740+2.67%
Close 11-13 16:00（ET）
3.47BMarket Cap
0.00P/E TTM
Parabilis Medicines Ord Shs (PBLS) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts
Strong Buy
3 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
41.400USD+46.19%
PBLS Analyst Recommendation Trends
In the current month, PBLS has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PBLS average Analyst price target in the last month is 41.400.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
0
0
0
0
0
3
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
5
4
0
0
0
0
0
PBLS Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, PBLS EPS is projected to reach -0.407 in FY2026Q4, following reported EPS of -0.360 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
--
0.08
-0.39
-0.41
-0.34
Actual
-0.60
-0.54
-0.36
--
--
Surprise
--
-777.57%
+8.48%
--
--
FAQs
What is Parabilis Medicines Ord Shs's expected revenue for the next quarter?
Parabilis Medicines Ord Shs's expected revenue is 629.60K.
What is Parabilis Medicines Ord Shs's price target?
Analysts forecast that Parabilis Medicines Ord Shs's price target is USD 41.40, with the highest forecast at USD 45.00 and the lowest forecast at USD 40.00.
How have Parabilis Medicines Ord ShsPBLS's recent earnings per share performed?
The market expectation was USD -0.36, while Parabilis Medicines Ord ShsPBLS's earnings per share (EPS) for the previous quarter was USD -0.54. EPS for the next quarter is expected at USD -0.34.
What is the analyst rating for Parabilis Medicines Ord Shs?
Based on the ratings of Parabilis Medicines Ord Shs's stock from 6 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.